Next Financial Group’s Ligand Pharmaceuticals LGND Stock Holding History

Next Financial Group’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-160	Closed	-$10K	–	2384
2020 Q3	$10K	Buy	+160	New	+$10.9K	﹤0.01%	1636
2020 Q2	–	Sell	-160	Closed	-$7K	–	1315
2020 Q1	$7K	Hold	160	–	–	﹤0.01%	1624
2019 Q4	$10K	Hold	160	–	–	﹤0.01%	1773
2019 Q3	$10K	Hold	160	–	–	﹤0.01%	1704
2019 Q2	$11K	Buy	+160	New	+$11.8K	﹤0.01%	1655
2019 Q1	–	Sell	-1,542	Closed	-$131K	–	1904
2018 Q4	$131K	Buy	1,542 +1,021	+196%	+$109K	0.03%	511
2018 Q3	$89K	Buy	+521	New	+$78.5K	0.04%	387
2017 Q4	–	Sell	-802	Closed	-$72K	–	900
2017 Q3	$72K	Hold	802	–	–	0.02%	594
2017 Q2	$61K	Hold	802	–	–	0.01%	715
2017 Q1	$56K	Hold	802	–	–	0.02%	681
2016 Q4	$51K	Hold	802	–	–	0.01%	955
2016 Q3	$51K	Hold	802	–	–	0.01%	933
2016 Q2	$59K	Hold	802	–	–	0.02%	606
2016 Q1	$53K	Hold	802	–	–	0.02%	607
2015 Q4	$54K	Buy	+802	New	+$49.5K	0.02%	599

Other funds holding LGND

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Next Financial Group's LGND Position: Q4 2020 in Review

Next Financial Group sold out of Ligand Pharmaceuticals (LGND) in Q4 2020, closing a stake of 160 shares — an estimated $10K sold.

Next Financial Group first reported a position in LGND in Q4 2015 and held it in 15 quarters. The position peaked at $131K in Q4 2018. 242 funds tracked by Wall St. Rank hold LGND as of Q4 2020.

Next Financial Group reported no remaining Ligand Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Next Financial Group sold 160 Ligand Pharmaceuticals shares in Q4 2020, an estimated $10K.
Next Financial Group first reported a position in Ligand Pharmaceuticals in Q4 2015 and held it in 15 quarters.
Next Financial Group's Ligand Pharmaceuticals position peaked at $131K in Q4 2018.
242 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q4 2020.

Based on Next Financial Group's 13F filing for Q4 2020, filed 5 Feb 2021.